Millionaires push human embryo gene editing despite scientific and ethical warnings.
The world of technology is rapidly moving toward the genetic editing of human embryos, a practice that is raising growing ethical, scientific, and social concerns. Although banned in most countries, startups and billionaires from Silicon Valley and the crypto world are investing millions of dollars to develop and legalize it.
One such company is Bootstrap Bio, co-founded by Chase Denecke and Ben Korpan, which seeks to modify the DNA of human embryos to eliminate hereditary diseases or enhance desired traits such as intelligence. The most controversial aspect is that these modifications would be hereditary — meaning they would be passed down to future generations.
Among its first investors are Malcolm and Simone Collins, a couple associated with magnate Elon Musk, who advocate for “pronatalism” and in vitro fertilization (IVF) to select embryos with allegedly superior traits. Some critics accuse them of promoting modern-day eugenics.
According to reports, Bootstrap Bio plans to begin clinical trials in Honduras between 2026 and 2027 — a strategy that may aim to bypass the strict regulations in the United States, where this practice is illegal.
Crypto Investors Join the Project.
Another key player is Brian Armstrong, billionaire founder of the Coinbase platform. In June, Armstrong publicly stated on the social network X (formerly Twitter) that he is seeking to assemble a team of experts in bioinformatics and genetic editing to launch his own company dedicated to embryo editing.
“Nearly 400 million people today live with a genetic disease. This technology can have a major impact on human health if implemented correctly,” Armstrong wrote, adding that it is time for a U.S. company to lead the field.
Armstrong also organized a private dinner with scientists to discuss the development of technologies such as artificial wombs and genetically assisted reproduction, attended by bioinformatician Lucas Harrington, who is also considering founding his own company in this sector.
A Divided Scientific Community.
While advocates present this technology as a medical revolution, the international scientific community remains divided and on alert.
According to the Center for Genetics and Society, in a June 2025 article:
“Proponents of heritable genome editing, who have enormous financial resources, are moving forward without regard for its safety, social, or eugenic risks.”
In May, various international scientific organizations proposed a 10-year moratorium on this technology. Tim Hunt, director of the Alliance for Regenerative Medicine, warned that germline editing poses “huge and complex challenges,” and that the medical need for its application in humans has not been demonstrated.
Other experts, such as Hank Greely, professor of bioethics at Stanford University, caution that the technology is untested and could have unpredictable consequences. “We have no idea what would happen to edited babies,” he concluded.
The most extreme case to date was that of Chinese scientist He Jiankui, who in 2018 announced the birth of the first genetically modified babies. He was sentenced to prison for illegal practices but has announced his intention to resume his research in the United States, despite having his passport confiscated.
A Point of No Return?
A recent MIT Technology Review article suggests that the ban on embryo gene editing in the United States could be lifted if a compelling medical use is demonstrated, or if influential figures manage to change regulations through political and economic pressure.
As some powerful actors invest in creating a new generation of “designer babies,” fears are growing that the ethical debate will be overshadowed by technological ambition and commercial interest.
The views expressed in this article are those of the author and do not necessarily represent the official position of Gateway Hispanic.
About The Author
